ArticleOcular oncology and pathology2026
Extraocular Extension in Melanoma at an Ocular Oncology Unit in Buenos Aires.
Article in Ocular oncology and pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Extrascleral extension (EOE) of uveal melanoma is a known negative prognostic factor, more frequently observed in medium to large tumors. Although EOE is typically limited in size, extensive cases present significant challenges in treatment planning, and the optimal management approach remains controversial. This study aimed to estimate the incidence of EOE in patients with uveal melanoma and analyze the prognosis of patients treated at the Italian Hospital of Buenos Aires from 2007 to June 2024. Methods: We conducted an observational, analytical, retrospective cohort study from 2007 to June 2024. Patients with EOE at diagnosis or during follow-up were identified. Epidemiological characteristics, tumor dimensions, timing of EOE, metastasis occurrence, and survival data were analyzed. Results: A total of 181 patients diagnosed with uveal melanoma were included, of whom twelve (6.62%) presented EOE, and 54.5% were male. The mean age was 64.41 years (SD 14.39). Six patients (50%) had EOE at diagnosis (average tumor thickness 9.51 mm, average diameter 17.7 mm), while six developed it during follow-up. The median time to event was 31.5 months (range: 8-120 months). Among these 12 patients, three developed metastases within the first year after diagnosis and treatment. Conclusions: EOE is a poor prognostic factor and tends to occur in larger tumors. It may be present at diagnosis or appear years later, reinforcing the need for long-term surveillance. Early identification is crucial to ensure appropriate treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.